NORWALK, Conn. & DENVER--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) and the Rocky Mountain Cancer Centers will hold the first MMRF Patient Summit in Denver on Saturday, March 25, 2017. This free educational program is designed to help patients and caregivers learn more about multiple myeloma, the second most common blood cancer, and how to optimize their journey with the disease. Program Chair Robert Rifkin, MD, FACP, from the Rocky Mountain Cancer Centers, will be joined by multiple myeloma experts who will discuss treatment options for all stages of the disease, clinical trials, and management of symptoms and side effects.
“Our MMRF Patient Summits empower patients and their caregivers by arming them with knowledge they need for the best possible outcome. Dr. Rifkin of the Rocky Mountain Cancer Centers is a long-time collaborator and we are thrilled to partner with him on this important program.” said Anne Quinn Young, MPH, Senior Vice President of Marketing and Communications at the MMRF. “We are also honored to have Dr. Bruce and Kathy Elsey of Dr. Elsey’s® Products as patient speakers at our Denver Patient Summit. They are an extraordinary inspiration to our organization, and we are grateful for the impact they have had in terms of generating much-needed funding to fuel new treatments and cures for patients, as well as help to educate the public about the mission of the MMRF to fuel innovation, foster collaboration and speed clinical trials.”
The agenda will cover treatment options for newly diagnosed patients, stem cell transplantation, relapsed/refractory disease, clinical trials, supportive care options, and managing bone disease. This free educational program will be held on Saturday, March 25th from 8:30 AM to 3:00 PM at Hyatt Regency Denver Tech Center – 7800 E Tufts Avenue, Denver, CO 80237.
Visit www.themmrf.org/Denver to register or contact Beth Ann Karlehag at karlehagb@themmrf.org
About Multiple Myeloma
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,280 adults (17,490 men and 12,790 women) in the United States will be diagnosed with MM in 2016 and an estimated 12,590 people are predicted to die from the disease. The five-year survival rate for MM is approximately 47%, versus 31% in 1999.
About the Multiple Myeloma Research Foundation (MMRF)
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients.
Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $330 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.
